Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year. New, potentially best-in-class ADC is targeting a tumor selective marker present in a broad spectrum of cancers with high medical need. Ingelheim, Germany, and Seoul, Korea, 15 October 2025 – Boehringer Ingelheim and AimedBio, [...]










